Geron Corp (GERN) - Financial and Strategic SWOT Analysis Review

Date: May 30, 2017
Pages: 45
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: G1AB95136E6EN
Leaflet:

Download PDF Leaflet

Geron Corp (GERN) - Financial and Strategic SWOT Analysis Review
Geron Corp (GERN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Geron Corp (Geron) is a clinical stage biopharmaceutical company, which develops a telomerase inhibitor as a potential treatment for cancer. The company is evaluating its flagship product candidate Imetelstat in two clinical trials: IMbark and IMerge in partnership with Janssen Biotech, Inc. IMbark is a Phase II, randomized, single-blind and multi-center study for patients with high risk myelofibrosis (MF) whose disease is relapsed after or refractory to JAK inhibitor treatment; and IMerge is a Phase 2/3, multi-center study of imetelstat in transfusion-dependent participants with low or intermediate-1 risk myelodysplastic syndrome (MDS). Geron also has collaboration and royalty agreements with companies in oncology, diagnostics, biologics and research tools production domains. Geron is headquartered in Menlo Park, California, the US.

Geron Corp Key Recent Developments

May 09,2017: Geron Reports First Quarter 2017 Financial Results and Recent Events
Mar 01,2017: Geron Reports Fourth Quarter and Annual 2016 Financial Results
Nov 03,2016: Geron Reports Third Quarter 2016 Financial Results and Recent Events
Aug 03,2016: Geron Corporation Reports Second Quarter 2016 Financial Results and Recent Events
May 05,2016: Geron Reports First Quarter 2016 Financial Results and Recent Events

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
strong>SECTION 1 - ABOUT THE COMPANY

Geron Corp - Key Facts
Geron Corp - Key Employees
Geron Corp - Key Employee Biographies
Geron Corp - Major Products and Services
Geron Corp - History
Geron Corp - Company Statement
Geron Corp - Locations And Subsidiaries
Head Office

SECTION 2 – COMPANY ANALYSIS

Geron Corp - Business Description
Geron Corp - SWOT Analysis
SWOT Analysis - Overview
Geron Corp - Strengths
Geron Corp - Weaknesses
Geron Corp - Opportunities
Geron Corp - Threats
Geron Corp - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Geron Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Geron Corp, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Geron Corp, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

May 09, 2017: Geron Reports First Quarter 2017 Financial Results and Recent Events
Mar 01, 2017: Geron Reports Fourth Quarter and Annual 2016 Financial Results
Nov 03, 2016: Geron Reports Third Quarter 2016 Financial Results and Recent Events
Aug 03, 2016: Geron Corporation Reports Second Quarter 2016 Financial Results and Recent Events
May 05, 2016: Geron Reports First Quarter 2016 Financial Results and Recent Events
Feb 25, 2016: Geron Reports Fourth Quarter and Annual 2015 Financial Results

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Geron Corp, Key Facts
Geron Corp, Key Employees
Geron Corp, Key Employee Biographies
Geron Corp, Major Products and Services
Geron Corp, History
Geron Corp, Key Competitors
Geron Corp, Ratios based on current share price
Geron Corp, Annual Ratios
Geron Corp, Annual Ratios (Cont.1)
Geron Corp, Interim Ratios
Geron Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Geron Corp, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Geron Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Geron Corp, Performance Chart (2012 - 2016)
Geron Corp, Ratio Charts
Geron Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Geron Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

COMPANIES MENTIONED

NS Pharma Inc
Incyte Corp
Gilead Sciences Inc
CTI BioPharma Corp
Acceleron Pharma Inc
Skip to top


Ask Your Question

Geron Corp (GERN) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: